AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

← Lung cancer: perioperative IO and KRAS NSCLC

ALK

Late-breaking

4 people · 6 posts · 3 abstracts

Other cases in this chapter

adebrelimabPerioperative EFS HR 0.52
taletrectinibROS1+ ORR 90%, DoR 49.7 mo
CheckMate 77THigh pCR only in ctDNA clearers
LCINS / Sherlock-Lung1,209 WGS: EGFR in never-smokers, KRAS in smokers

Evidence

4618

TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases

Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella

Read the abstract →

5787

TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins and leads to regression of ALK TKI-refractory tumors

Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Lauren Highfield, Nobuyuki Kondo, Aaron N. Hata, Kenneth Ngo, Jisu Lee, Prafulla C. Gokhale, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella

Read the abstract →

LB013

Lorlatinib in advanced ALK-positive non-small cell lung cancer: Efficacy, safety and exploration of predictive biomarkers for therapeutic response

Fang Wei, Linyan Tian, Huiyang Shi, Wenxin Jiang, Danru Zheng, Haiyan Xu, Yan Wang

Read the abstract →

Floor

Apr 23Thu

Thursday · 1 items